Efficacy of CS-758, a novel triazole, against experimental fluconazole-resistant oropharyngeal candidiasis in mice

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 2, 2003, Pages 601-606

  Kamai, Yasuki ^a   Kubota, Mikie ^a   Fukuoka, Takashi ^a   Kamai, Yoko ^a   Maeda, Naoyuki ^a   Hosokawa, Tsunemichi ^a   Shibayama, Takahiro ^a   Uchida, Katsuhisa ^b   Yamaguchi, Hideyo ^b   Kuwahara, Shogo ^c  

^a DAIICHI SANKYO CO   (Japan)

^b TEIKYO UNIVERSITY   (Japan)

^c TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 [5 [2 (2,4 DIFLUOROPHENYL) 2 HYDROXY 1 METHYL 3 (1H 1,2,4, TRIAZOL 1 YL)PROPYLTHIO] 1,3 DIOXAN 2 YL] 1,3 BUTADIENYL] 3 FLUOROBENZONITIRLE; ANTIFUNGAL AGENT; FLUCONAZOLE; ITRACONAZOLE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CELL COUNT; CELL VIABILITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; DRUG RESISTANCE; DRUG SENSITIVITY; EVALUATION; HISTOPATHOLOGY; IN VITRO STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; OROPHARYNX; PREDICTION; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; STRAIN DIFFERENCE; THRUSH;

ANIMALS; ANTIFUNGAL AGENTS; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; FLUCONAZOLE; MALE; MICE; MICROBIAL SENSITIVITY TESTS; OROPHARYNX; TONGUE; TRIAZOLES;

EID: 0037311183     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.2.601-606.2003     Document Type: Article

References (22)

1. Elewski, B. E., and R. J. Hay. 1996. Cutaneous antifungal therapy in AIDS: summary of an international summit. Infect. Dis. Clin. Pract. 5:359-370.
2. Greenspan, D. 1994. Treatment of oropharyngeal candidiasis in HIV-positive patients. J. Am. Acad. Dermatol. 31:S51-S55.
3. Hostetler, J. S., L. H. Hanson, and D. A. Stevens. 1992. Effect of cyclodextrin on the pharmacology of antifungal oral azoles. Antimicrob. Agents Chemother, 36:477-480.
4. Humphrey, M. J., S. Jevons, and M. H. Tarbit. 1985. Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans. Antimicrob. Agents Chemother. 28:648-653.
5. Kamai, Y., T. Harasaki, T. Fukuoka, S. Ohya, K. Uchida, H. Yamaguchi, and S. Kuwahara. 2002. In vitro and in vivo activities of CS-758 (R-120758), a new triazole antifungal agent. Antimicrob. Agents Chemother. 46:367-370.
6. Kamai, Y., M. Kubota, Y. Kamai, T. Hosokawa, T. Fukuoka, and S. G. Filler. 2001. New model of oropharyngeal candidiasis in mice. Antimicrob. Agents Chemother. 45:3195-3197.
7. Kamai, Y., M. Kubota, Y. Kamai, T. Hosokawa, T. Fukuoka, and S. G. Filler. 2002. Contribution of Candida albicans ALS1 to the pathogenesis of experimental oropharyngeal candidiasis. Infect. Immun. 70:5256-5258.
8. Klein, R. S., A. H. Carol, C. B. Small, B. Moll, M. Lesser, and G. H. Friedland. 1984. Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome. N. Engl. J. Med. 311: 354-358.
9. Law, D., C. B. Moore, H. M. Wardle, L. A. Ganguli, M. G. Keaney, and D. W. Denning. 1994. High prevalence of antifungal resistance in Candida spp. from patients with AIDS. J. Antimicrob. Chemother. 34:659-668.
10. National Committee for Clinical Standards. 1997. Reference method for broth microdilution antifungal susceptibility testing of yeasts. Approved standard M27-A. National Committee for Clinical Standards, Wayne, Pa.
11. Odds, F. C. 1996. Resistance of clinically important yeasts to antifungal agents. Int. J. Antimicrob. Agents 6:145-147.
12. Petraitis, V., R. Petraitiene, A. H. Groll, T. Sein, R. L. Schaufele, C. A. Lyman, A. Francesconi, J. Bacher, S. C. Piscitelli, and T. J. Walsh. 2001. Dosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis. Antimicrob. Agents Chemother. 45:471-479.
13. Powderly, W. G. 1994. Resistant candidiasis. AIDS Res. Hum. Retrovir. 10:925-929.
14. Quart, A., A. Espinel-Ingroff, and D. Reich. 1995. Fluconazole for refractory oropharyngeal candidiasis in AIDS patients. AIDS Patient Care 9:56-59.
15. Redding, S., J. Smith, G. Farinacci, M. Rinaldi, A. Fothergill, J. Rhinechalberg, and M. Pfaller. 1994. Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS - documentation by in vitro susceptibility testing and DNA subtype analysis. Clin. Infect. Dis. 18:240-242.
16. Rex, J. H., M. G. Rinaldi, and M. Pfaller. 1995. Resistance of Candida species to fluconazole. Antimicrob. Agents Chemother. 39: 1-8.
17. Samaranayake, L. P., and P. Holmstrup. 1989. Oral candidiasis and human immunodeficiency virus infection. J. Oral Pathol. Med. 18:554-564.
18. Sangeorzan, J. A., S. F. Bradley, X. He, L. T. Zarins, G. L. Ridenour, R. N. Tiballi, and C. A. Kauffman. 1994. Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance. Am. J. Med. 97:339-346.
19. Simon, M. R., W. L. Houser, K. A. Smith, and P. M. Long. 1997. Esophageal candidiasis as a complication of inhaled corticosteroid. Ann. Allergy Ashma Immunol. 79:333-338.
20. Spector, S. L., C. W. Wangaard, and E. J. Bardana, Jr. 1982. The use of cultures and immunologic procedures to predict oropharyngeal candidiasis in patients on steroid aerosol. Clin. Allergy 12:269-278.
21. Twycross, R. 1994. The risks and benefits of corticosteroids in advanced cancer. Drug Safety 11:163-178.
22. Walsh, T. J., C. E. Gonzalez, S. Piscitelli, J. D. Bacher, J. Peter, R. Torres, D. Shetti, V. Katsov, K. Kligys, and C. A. Lyman. 2000. Correlation between in vitro and in vivo antifungal activities in experimental fluconazole-resistant oropharyngeal and esophageal candidiasis. J. Clin. Microbiol. 38:2369-2373.